- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02473991
Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
The investigator will make certain that the appropriate informed consent process is in place to ensure that potential research subjects, or their authorized representatives, are fully informed about the nature and objectives of the study, the potential risk and benefits of study participation, and their right as research subjects.
All laboratory specimens, evaluation forms, reports, video recordings, and other records that leave the site will not include unique personal data to maintain subject confidentiality.
All patients provided an informed written consent after they were fully instructed about the investigation.The study was approved by ethical committee of Ain Shams University.
All recruited women were observed at the 1st trimester screening at antenatal clinic and assessed for baseline demographic and obstetric data including age, parity, body mass index (BMI) and past medical events. Smoking, alcohol and drug use were also determined.
At second and third trimester (15-20 and 30-34 weeks of gestation respectively), the maternal weight, weight gain, BMI, BMI gain and data of ultrasound examination were recorded. At the time of delivery after assessment of maternal weight as mentioned above, the birth weight (in grams), fetal sex, and mode of delivery were taken.
All pregnant women underwent ultrasound evaluation of placental thickness at the time of second trimester (15-20 weeks of gestation) as well as third trimester (30-34 weeks of gestation).
All sonographic examinations were performed trans-abdominal using a Medison X4 ultrasound machine Trans abdominal4.0 megahertz (MHz) probe at The Special Care Center for Fetus Unit at Ain Shams University Maternity Hospital.
The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion as described by Hoddick et al
Each evaluation was performed by one of two experienced sonographers of our hospital with minimum inter- and intra-observer variability.
After delivery, the placenta was weighed in grams as previously described by Azpurua et al.
Fetal weight (primary objective) and neonatal status and morbidity including baby Apgar scores, fetal distress or fetal death and admission to the neonatal intensive care unit were also determined. All the examinations and data recording were performed by two senior resident physicians.(secondary objective)
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Elabbasia
-
Cairo, Elabbasia, Egipto
- Ain Shams Faculty of Medicine
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- patient Aged between 18 and 45 years.
- singleton viable pregnancy.
- non scared uterus.
Exclusion Criteria:
- systemic illness (DM,Hypertension, renal disease, liver disease, sickle cell disease)
- known congenital fetal anomalies.
- multiple pregnancy.
- intra uterine fetal death.
- anatomical defect of pregnant uterus
- abnormally located placenta or placental anomalies
- morbid obesity
- missing records
- unwilling to incorporate in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fetal Weight (Fetal Weight at Birth)
Periodo de tiempo: 9 months
|
Fetal weight (fetal weight at birth) (in grams)
|
9 months
|
|
Placental Thickness in Second Trimester
Periodo de tiempo: 15-20 weeks of gestation
|
placental thickness measured in millimeter
|
15-20 weeks of gestation
|
|
Placental Thickness at 3rd Trimester
Periodo de tiempo: 30-34 weeks of pregnancy
|
30-34 weeks of pregnancy
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: AHMED MEKLED, Professor, Ain Shams University
- Director de estudio: HAYTHAM SABAA, Lecturer, Ain Shams University
Publicaciones y enlaces útiles
Publicaciones Generales
- Azpurua H, Funai EF, Coraluzzi LM, Doherty LF, Sasson IE, Kliman M, Kliman HJ. Determination of placental weight using two-dimensional sonography and volumetric mathematic modeling. Am J Perinatol. 2010 Feb;27(2):151-5. doi: 10.1055/s-0029-1234034. Epub 2009 Aug 3.
- Hoddick WK, Mahony BS, Callen PW, Filly RA. Placental thickness. J Ultrasound Med. 1985 Sep;4(9):479-82. doi: 10.7863/jum.1985.4.9.479.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades del sistema endocrino
- Complicaciones de la diabetes
- Diabetes mellitus
- Peso corporal
- Enfermedades Fetales
- Complicaciones del embarazo
- Trastornos del crecimiento
- Diabetes Gestacional
- Embarazo en diabéticos
- Peso de nacimiento
- Retraso del crecimiento fetal
- Macrosomía fetal
- Peso Fetal
Otros números de identificación del estudio
- Master degree in Obs & gyn
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre ultrasound
-
McGill University Health Centre/Research Institute...Aún no reclutandoCancer de prostata | Vigilancia Activa del Cáncer de Próstata | Técnicas de ImagenCanadá
-
ReCor Medical, Inc.ReclutamientoHipertensiónAustria, Suiza, Alemania, Bélgica, Países Bajos, Reino Unido, Francia, Mónaco, España
-
Medical Corps, Israel Defense ForceReclutamientoLesiones Traumáticas | Herida de hemorragiaIsrael
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminadoMedición Doppler de la arteria uterinaPaíses Bajos
-
National Taiwan University HospitalTrust Bio-sonics, Inc.Aún no reclutandoMetástasis hepática | Adenocarcinoma de páncreas metastásicoTaiwán
-
Riverside University Health System Medical CenterDesconocidoPacientes en estado de shock e intubados en Trauma Bay (TB)Estados Unidos
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology; St. Olavs HospitalTerminadoCarrera | Ataque isquémico transitorio | Ataque Isquémico, Transitorio | Accidente cerebrovascular | Apoplejía cerebrovascularNoruega
-
Ajou University School of MedicineTerminadoEstenosis de la arteria coronariaCorea, república de
-
University of Erlangen-Nürnberg Medical SchoolReclutamientoLeucemias linfoblásticas agudas (LLA) | Seguimiento a largo plazoAlemania
-
Sherin RefaatTerminado